PeerVoice Clinical Pharmacology Audio

By PeerVoice

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

  1. 1.
    A Multidisciplinary Approach to Prevention and Management of CKD in T2DM: Best Practices for Optimal Outcomes
    28:53
  2. 2.
    An Immune System in Double Trouble: What Is ‘Best Practice’ for Managing Patients With Lymphoproliferative Malignancies?
    41:28
  3. 3.
    The Holistic Care of Patients with T2DM: Going Beyond HbA1c
    23:07
  4. 4.
    Therapeutic Sequencing in Patients With Advanced or High Risk Hodgkin Lymphoma: Strategies in Action
    20:47
  5. 5.
    Clinical Conundrums in Type 2 Diabetes: Managing Challenging Cases in Primary Care
    25:47
  6. 6.
    Clinical Developments in Managing Autoinflammatory Diseases
    30:22
  7. 7.
    Acute Psychosis: When to Suspect Acute Hepatic Porphyria
    18:12
  8. 8.
    Raising the Bar in Heart Failure Management: 2021 Congress Updates on SGLT2 Inhibitors
    12:48
  1. 9.
    Treatment Gaps in T2DM and Obesity: Personalising Care for Better Outcomes
    31:27
  2. 10.
    Personalising Care Across the Disease Continuum: From Prediabetes Through Type 2 Diabetes
    44:02
  3. 11.
    Evaluating the Evidence for SGLT2 Inhibition in CKD: Highlights From the 2021 Virtual ERA-EDTA Congress
    8:39
  4. 12.
    Identifying Bowel Urgency in Patients With Ulcerative Colitis: The Need for Speed
    59:57
  5. 13.
    Suspecting, Diagnosing and Managing Multifocal Motor Neuropathy: A Patient Investigation
    49:02
  6. 14.
    Immunotherapies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Which Antibodies for Which Patients?
    58:25
  7. 15.
    Going the Distance in HIV: Simplifying ART at Every Stage
    24:03
  8. 16.
    Checkpoint Inhibitors for Advanced or Recurrent Endometrial Cancer: A New Standard of Care?
    26:47
  9. 17.
    If I'd Known Then What I Know Now: Recognising My First AHP Patient
    18:33
  10. 18.
    Evaluating the Evidence for Managing CKD: Highlights From World Congress of Nephrology 2021
    8:44
  11. 19.
    Easy to Treat vs Easy to Manage Patients With HCV: What’s the Difference?
    29:28
  12. 20.
    Advanced Basal Cell Carcinoma: An Exploration of Clinical Challenges and What the Future Could Hold
    58:49
  13. 21.
    Step-by-Step: Setting a Course for Long-Term Control of Type 2 Diabetes With GLP-1 RAs
    21:16
  14. 22.
    Checking In on Checkpoint Inhibitors: Current and Emerging Strategies for High PD-L1–Expressing Tumours in Advanced NSCLC
    29:24
  15. 23.
    Biologics and Beyond in Atopic Dermatitis: Emerging Targets and How They Work
    22:11
  16. 24.
    Why Combination Therapies and Why Now? The Rationale and Role of GLP-1 RAs and Insulin
    32:52
  17. 25.
    Unmet Needs in Familial Mediterranean Fever (FMF): Real-Life Data, the Patient Perspective, and the Role of Anti–IL-1 Therapy
    59:05
  18. 26.
    Asked and Answered: Differentiating Between PARP Inhibitors in First-Line Advanced Ovarian Cancer
    27:28
  19. 27.
    GP Empowerment: Eliminating HCV From the Front Line
    29:21
  20. 28.
    "Setting New Goals for Slowing Progression in Chronic Kidney Disease: What Is Possible With GLP-1 RAs?"
    39:04
  21. 29.
    If You Suspect, Test! The Important First Steps to Preventing the Devastating Consequences of Hepatitis
    19:48
  22. 30.
    Is It the Carrot or the Stick? Practical Strategies for Improving Adherence to Antidiabetic Therapy
    25:58
  23. 31.
    Can Long-Acting Injectables Make a Difference in HIV?
    25:43
  24. 32.
    Optimising HBV Treatment Outcomes Whilst We Hunt for a Cure
    17:55
  25. 33.
    Understanding Hypercapnia in Adult Respiratory Distress Syndrome: The Quest for Optimal Patient Outcomes
    12:56
  26. 34.
    Evolving the Treatment Paradigm in Metastatic HER2-Positive Breast Cancer: The Ongoing Story of Emerging Treatments
    15:09
  27. 35.
    GnRH Antagonist vs LHRH Agonist: To Desensitize or To Inhibit, That Is the Question!
    19:14
  28. 36.
    The First Biologic in IBD: When, Which, and Why?
    29:55
  29. 37.
    Practical Strategies in Optimising Subcutaneous Immunoglobulin Replacement Therapy
    1:01:13
  30. 38.
    Stroke Prevention, Type 2 Diabetes, and GLP-1 Receptor Agonists: What Neurologists Need to Know
    44:48
  31. 39.
    Beyond HPIs for Advanced Basal Cell Carcinoma: Exploring the Clinical Implications of New Evidence
    19:46
  32. 40.
    Modern Management of Chronic Kidney Disease: A Look to the Future
    10:33
  33. 41.
    Cardiovascular Risk and Prostate Cancer: Clinical Perspectives on ADT
    22:25
  34. 42.
    Proactive IBD Care: Identifying Patients at Risk of Disease Progression
    23:36
  35. 43.
    Interpreting the Most Recent Clinical Data With A Real-World Lens: Implications on Hepatocellular Carcinoma Management
    16:01
  36. 44.
    The Impact of Earlier Diagnosis and Timelier Treatment of Primary Hyperoxaluria Type 1
    19:59
  37. 45.
    Simplifying Fluid Therapy: Critical Care for the Critically Ill
    17:11
  38. 46.
    SGLT2 Inhibition for HF: Evidence From Virtual Scientific Sessions 2020
    37:43
  39. 47.
    A Look at Emerging SMA Outcomes: Highlights of WMS 2020
    9:12
  40. 48.
    Prevention and Acute Management of Migraine: Updates From London
    18:07
  41. 49.
    Evaluating the Evidence for SGLT2 Inhibition in CKD: Highlights of Kidney Week 2020
    10:13
  42. 50.
    Novel Strategies for Chronic Kidney Disease: New Data, New Paradigm?
    21:51

Listen to PeerVoice Clinical Pharmacology Audio now.

Listen to PeerVoice Clinical Pharmacology Audio in full in the Spotify app